StemCyte, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared an Expanded Access (EA) program for RegeneCyte®, the company's FDA-licensed hematopoietic progenitor cell ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 26, 2026--United Therapeutics Corporation (Nasdaq: UTHR) today announced positive results from its phase 1 study of miroliverELAP®, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results